Results 41 to 50 of about 6,662 (219)

Antifibrinolytic drugs and perioperative hemostasis [PDF]

American Journal of Hematology, 1997
Although excessive bleeding is widely recognized as a common complication of cardiac surgery, the recent success of antifibrinolytic drugs as prophylactic hemostatic agents has received little attention outside the surgical literature. The etiology of the coagulopathy following cardiac surgery is clearly multifactorial; however, the success of ...
Charles S. Greenberg, Thomas F. Slaughter   +1 more
openaire   +3 more sources

Management of dental extraction in patients with Haemophilia A and B: a report of 58 extractions [PDF]

, 2014
Objectives: Patients with inherited bleeding disorders are at high risk of bleeding following oral surgery and present challenges to the oral surgeons. Aim of this study was to report our experience in dental extraction in patients exhibiting Haemophilia
Peisker, Andre, Raschke, Gregor-Franziskus, Schultze Mosgau, Stefan   +2 more
core   +1 more source

Perioperative hyperfibrinolysis – physiology and pathophysiology

Brazilian Journal of Anesthesiology, 2021
Introduction and objectives: The role of the anesthesiologist in the perioperative management of hemostasis has attracted increasing attention. The fibrinolytic system participates in hemostasis, removing clots after repair of the vascular injury.
David Silveira Marinho
doaj   +1 more source

Using antifibrinolytics to tackle neuroinflammation

Neural Regeneration Research, 2020
Plasmin is generally known as a promotor of inflammation. Recent advancement suggests that it has a complex role as immunity modulator. Pharmacological inhibition of plasmin production and activity has been proven to improve neurological outcomes in traumatic brain injury and subarachnoid hemorrhage, most probably by preventing re-bleeding.
Atsev, Stanimir, Tomov, Nikola Stefanov
openaire   +5 more sources

In Vivo Assessment of Thermosensitive Liposomes for the Treatment of Port Wine Stains by Antifibrinolytic Site-Specific Pharmaco-Laser Therapy

Pharmaceutics, 2020
Antifibrinolytic site-specific pharmaco-laser therapy (SSPLT) is an experimental treatment modality for refractory port wine stains (PWS). Conceptually, antifibrinolytic drugs encapsulated in thermosensitive liposomes are delivered to thrombi that form ...
Mingjuan Li, M. Ingmar van Raath, Shervin Khakpour, Ahmet Seçilir, Bart C. Sliggers, Xuan Huang, Baoyue Ding, Gert Storm, René R. van der Hulst, Anton I.P.M. de Kroon, Michal Heger   +10 more
doaj   +1 more source

Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk [PDF]

, 2017
An enhanced thrombotic environment and premature atherosclerosis are key factors for the increased cardiovascular risk in diabetes. The occlusive vascular thrombus, formed secondary to interactions between platelets and coagulation proteins, is composed ...
A Agren, A Ceriello, A Hamsten, A Hamsten, A Lados-Krupa, A Liang, A Lutjens, A Rouch, A Rupin, A Sahebkar, A Tripodi, A Undas, A Undas, A Undas, AH Guimaraes, AH Henschen-Edman, AH Straten van, AS Wolberg, AS Wolberg, B Blomback, B Craen Van De, B Lipinski, B Rocca, B Wiman, B Zinman, BH Shieh, C Longstaff, CH Lundgren, CH Nair, CL Nikolajsen, CS Fox, D Capodanno, D Hill, D Leenaerts, D Ricklin, DA Gabriel, DA Lawrence, DA Lawrence, Darren Tomlinson, DJ Schneider, DL Crandall, DV Sakharov, E Angelantonio Di, E Chow, E Ernst, E Pretorius, E Pretorius, E Shacter, E Vercauteren, EG Levin, EJ Dunn, EJ Dunn, EL Hethershaw, EM Sherif, F Denorme, F Rollini, G Boden, G Gajos, G Jorneskog, GJ Brouwers, GK Hansson, GL Booth, GL Reed 3rd, GL Reed 3rd, H Elokdah, H Ritchie, HC Gerstein, HH Versteeg, HJ Beijers, HK Kim, I Juhan-Vague, I Shimomura, J Bester, J Danesh, J Montaner, J Svensson, J Weisel, JA Dormandy, JC Chapin, JD Mills, JG Dillinger, JH Foley, JL Ferreiro, JL Mega, JM Howes, JP Collet, JP Collet, JW Weisel, K Bangert, K Buelens, K Distelmaier, K Fatah, K Hess, K Hess, K Hess, K Leander, K Leander, Katherine Kearney, KE Brummel, Kerrie Smith, KN Lee, KN Lee, KN Lee, KN Lee, KN Lee, KR Machlus, L Badimon, L Ryden, L Wallentin, LM Belalcazar, M Konieczynska, M Pieters, M Pieters, M Pieters, M Rigla, M Udvardy, MA Bailey, MB Kahn, MC Alessi, ME Carr Jr, ME Meltzer, ME Meltzer, ME Meltzer, ME Stegenga, MG Marini, MR Hammer, MS Ardawi, N Gogitidze Joy, N Zheng, NH Tilburg van, NV Gorlatova, O Sigurdardottir, OJ Phung, P Chudy, P Clemmensen, P Katz, P Kohli, P Soma, P Soma, R Ajjan, R Favier, R King, RA Ajjan, RA Ajjan, RA Al-Horani, Ramzi Ajjan, RM Cubbon, RM Missov, RP Rother, RR Holman, S James, S Kimura, S Kimura, S Neergaard-Petersen, S Schulman, S Tehrani, S Tehrani, S Yener, SD Wiviott, SD Wiviott, SH Alzahrani, SH Alzahrani, SJ Cleland, SK Kunutsor, SL Carpenter, SP Marso, SR Fraser, ST Lord, T Koyama, T Kumada, T Lisman, T Plug, T Sasaki, T Tamaki, T Wyseure, T Wyseure, TC Holten van, TW Meade, U Amara, V Baeriswyl, VR Richardson, WB Kannel, X Zhou, X Zhou, Y Hori, Y Sakata, Y Sakata, Y Sakata, Y Sumi, Y Yano, YM Fortenberry, Z Valnickova   +191 more
core   +2 more sources

Current research progress of tranexamic acid in the management of patients with traumatic injuries in emergency settings

Frontiers in Disaster and Emergency Medicine
IntroductionThe trauma is a leading cause of global mortality, with hemorrhage being a major contributor. Tranexamic acid (TXA), an antifibrinolytic agent, has shown promise in reducing blood loss and improving outcomes in trauma patients.
Gengwei Zhang, Juan Liu, Zhang Wen, Zhang Wen, Jia He, Haifeng Chang   +5 more
doaj   +1 more source

The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients

Türk Biyokimya Dergisi, 2022
Studies have shown that fibrinolysis activity is insufficient in COVID-19 patients. Plasminogen activator inhibitor-1 (PAI-1) is an important antifibrinolytic molecule that plays a key role in the fibrinolytic system.
Baltan Ecem, Serin Erdinç, Avci Burak Yasin, Akilli Işil Kibar, Çinar Ayşe Sürhan   +4 more
doaj   +1 more source

Traumatic injury clinical trial evaluating tranexamic acid in children (TIC-TOC): study protocol for a pilot randomized controlled trial. [PDF]

, 2018
BACKGROUND: Trauma is the leading cause of morbidity and mortality in children in the United States. The antifibrinolytic drug tranexamic acid (TXA) improves survival in adults with traumatic hemorrhage, however, the drug has not been evaluated in a ...
Adelson, P David, Barnhard, Sarah E, Bobinski, Matthew, Ghetti, Simona, Hewes, Hilary A, Holmes, James F, Kuppermann, Nathan, Michael Dean, J, Myers, Sage R, Nishijima, Daniel K, Roberts, Ian, Schalick, Walton O, Stanley, Rachel M, TIC-TOC Collaborators of the Pediatric Emergency Care Applied Re, Tran, Nam K, Tzimenatos, Leah S, VanBuren, John   +16 more
core   +2 more sources

Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes [PDF]

, 2017
Purpose: Tranexamic acid (TXA) is a widely used antifibrinolytic agent that can also cause a decrease in vascular permeability. We hypothesized that TXA could improve macular edema (ME) that is caused by an increase in retinal vascular permeability.
Gosho Masahiko, Iwaki Masayoshi, Kamei Motohiro, Sugita Keijiro, Takeuchi Fumio, Takeyama Masayuki, Zako Masahiro, 五所 正彦   +7 more
core   +3 more sources